Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) traded down 1.6% on Monday . The company traded as low as $2.38 and last traded at $2.40, with a volume of 221,565 shares traded. The stock had previously closed at $2.44.

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a research report on Saturday, July 9th. FBR & Co upped their target price on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 4th. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a research report on Friday, May 6th. Piper Jaffray Cos. reissued an “overweight” rating and set a $4.00 price objective (down from $6.00) on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Finally, Janney Montgomery Scott reissued a “hold” rating and set a $4.00 price objective on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. BioDelivery Sciences International has an average rating of “Hold” and an average target price of $8.25.

The company’s market cap is $132.49 million. The stock’s 50 day moving average price is $2.55 and its 200 day moving average price is $2.89.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The firm earned $5 million during the quarter, compared to the consensus estimate of $3.35 million. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. The business’s revenue for the quarter was up 194.1% compared to the same quarter last year. On average, analysts forecast that BioDelivery Sciences International Inc. will post ($1.14) earnings per share for the current year.

In other news, Director William B. Stone sold 16,000 shares of the business’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total transaction of $41,120.00. Following the sale, the director now owns 122,675 shares in the company, valued at $315,274.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.